ArsenalBio
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $325M
Overview
Engineering computationally designed, CRISPR-edited T cell therapies to treat solid cancers.
Oncology
Technology Platform
A programmable cell therapy platform integrating CRISPR gene editing, synthetic biology, and computational tools to engineer multifunctional T cells.
Funding History
1Total raised:$325M
Series C$325M
Opportunities
Success in solid tumors represents a massive market expansion beyond the hematologic cancers addressed by first-generation CAR-Ts.
Risk Factors
Faces significant scientific hurdles in solid tumor biology, manufacturing complexity, and potential safety concerns from gene editing.
Competitive Landscape
Competes with other next-gen cell therapy companies (e.g., Affini-T, Obsidian, Lyell) also targeting solid tumors with engineered T cells and gene editing.